The invention provides a bufarenogin and application of derivatives or pharmaceutically acceptable salts thereof. Results of in vivo and in vitro experiments show that bufarenogin can cause cycle arrest of hepatocarcinoma cells, restrain cell multiplication and induce cell apoptosis. Thus, the bufarenogin, and the derivatives or the pharmaceutically acceptable salts thereof can be used for preparing medicines for treating various tumors, including hepatocarcinoma.